Italian Horizon Scanning Project

Un sistema di allerta precoce per farmaci emergenti
Articolo Originale



The often modest therapeutic value, the uncertain level of innovation, and the high costs of new drugs suggest a pressing need for early evaluation of emerging pharmaceuticals. The Italian Horizon Scanning Project (IHSP) critically reports on emerging drugs in order to timely assess their potential impact on the National Health System.


IHSP identifies, filters and prioritizes emerging drugs for which a European Marketing Authorization (MA) is expected within 12–36 months. The final New Product Information Report, issued 12 months before the MA, critically reports on efficacy and safety of selected drugs, on their possible level of innovation, place in therapy and social and economic impact.


Since 2008, 39 new drugs were prioritized (corresponding to 44 indications) due to (i) their potential high epidemiological and economic impact; (ii) the limited availability or the complete lack of treatments; (iii) the uncertainty of the possible place in therapy of the emerging drug; (iv) the possible better efficacy and/or safety profile or possible better compliance of the new medicine versus the available therapies. Among the 39 drugs, 14 active principles were indicated in cancer patients, eight for cardiovascular diseases, and four for multiple sclerosis.


Horizon Scanning is a useful tool to support policy-makers in allocating resources more efficiently.


  1. 1.
    Stevens A, Milne R, Lilford R, Gabbay J. How do new technologies get into practice? Keeping pace with new technologies: systems needed to identify and evaluate them. Br Med J. 1999;319:1291–4. CrossRefGoogle Scholar
  2. 2.
  3. 3.
    Joppi R, Bertelè V, Garattini S. Disappointing biotech. Br Med J. 2005;331:895–7. CrossRefGoogle Scholar
  4. 4.
    Bertelè V, Banzi R, Capasso F, et al.. Haematological anticancer drugs in Europe: any added value at the time of approval? Eur J Clin Pharmacol. 2007;63:713–9. PubMedCrossRefGoogle Scholar
  5. 5.
    Garattini S, Bertelè V. How can we regulate medicines better? Br Med J. 2007;335:803–5. CrossRefGoogle Scholar
  6. 6.
    Hailey D, Topfer LA, Willis F. Providing information on emerging health technologies to provincial decision makers: a pilot project. Health Policy. 2001;58:15–26. PubMedCrossRefGoogle Scholar
  7. 7.
    Packer C. The National Horizon Scanning Centre (NHSC): early warning for new and emerging health technologies in England. BCM Public Health. 2005;9:410–3. Google Scholar
  8. 8.
    Joppi R, Demattè L, Menti AM, et al.. The Italian horizon scanning project. Eur J Clin Pharmacol. 2009;65:775–81. PubMedCrossRefGoogle Scholar
  9. 9.
  10. 10.
    Wiviott SD, Braunwald E, McCabe CH, et al.. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15. PubMedCrossRefGoogle Scholar
  11. 11. Accesso del 24/09/2012.
  12. 12.
    Italian Horizon Scanning Project. Euroscan Newsletter n. 7, November 2009. Accesso del 24/09/2012.
  13. 13.
    Emerging technologies in stroke. Euroscan Newsletter n. 11, December 2011. Accesso del 24/09/2012.
  14. 14.
    Horizon scanning and nephrology. Euroscan Newsletter n. 12, giugno 2012. Accesso del 24/09/2012.
  15. 15. Accesso del 24/09/2012.
  16. 16. Accesso del 24/09/2012.
  17. 17.
    Joppi R, Wild C. Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma. DSD: Horizon Scanning in Oncology 23. 2012. Accesso del 24/09/2012.
  18. 18.
    Poggiani C, Hintringer K. Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC). DSD: horizon scanning in oncology 21. 2012. Accesso del 24/09/2012.
  19. 19.
    Joppi R, Nachtnebel A. Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma. DSD: horizon scanning in oncology 30. Accesso del 24/09/2012.
  20. 20.
    Rini BI, Escudier B, Tomczak P, et al.. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9. PubMedCrossRefGoogle Scholar
  21. 21.
    Axitinib (Inlyta). Public Assessment Report. Procedure No. EMEA/H/C/002406. Accesso del 24/09/2012.
  22. 22.
    Fampridina (Famprya). Public Assessment Report. Procedure No. EMEA/H/C/002097. Accesso del 24/09/2012.
  23. 23.
    Prasugrel (Efient). Public Assessment Report. Procedure No. EMEA/H/C/000984. Accesso del 24/09/2012.
  24. 24.
    Ivacaftor (Kalydeco). Public Assessment Report. Procedure No.: EMEA/H/C/002494//0000. Accesso del 24/09/2012.
  25. 25.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.UOSD Sperimentazione clinica e valutazione farmaci, Dipartimento FarmaceuticoAzienda Ulss 20 di VeronaVeronaItalia

Personalised recommendations